From: Effect of erythropoietin-stimulating agent on uremic inflammation
Age, years | 65.5 ± 13.7 |
---|---|
Male sex (%) | 611 (67.9) |
BMI, kg/m2 | 23.0 ± 4.0 |
SBP, mmHg | 153 ± 26 |
DBP, mmHg | 78 ± 15 |
CTR, % | 54 ± 7 |
Primary disease | Â |
Chronic glomeruronephritis | 226 (25.1) |
Diabetic nephropathy | 432 (48.0) |
Glomerulosclerosis | 104 (11.6) |
Polycystic kidney disease | 28 (3.1) |
Post-renal disease | 5 (0.6) |
Others | 105 (11.6) |
Duration of nephrologist care, months | 33 ± 43 |
WBC, /mm3 | 6160 ± 1270 |
Hemoglobin, g/dL | 8.5 ± 1.5 |
Plt x 104, mm3 | 19.4 ± 7.1 |
Albumin, g/dL | 3.3 ± 0.6 |
LDL-C, mg/dL | 98 ± 41 |
HDL-C, mg/dL | 47 ± 17 |
Creatinin, mg/dL | 9.5 ± 3.5 |
BUN, mg/dL | 89 ± 27 |
Uric acid, mg/dL | 8.6 ± 2.2 |
eGFR, mL/min/1.73 m2 | 5.4 ± 2.9 |
Calcium, mg/dL | 7.8 ± 1.0 |
Phosphate, mg/dL | 6.0 ± 1.6 |
Intact-PTH, pg/mL | 304 ± 214 |
CRP, mg/dL | 0.48 ± 0.68 |
HCO3-, mmol/L | 18.9 ± 5.0 |
ESA (%) | 614 (68.2) |
ESA dose, u/month | 17813 ± 6580 |
ARB (%) | 489 (54.3) |
ACE-I (%) | 165 (16.3) |
ARB or ACE-I (%) | 541 (60.1) |
ARB and ACE-I (%) | 113 (12.6) |
CCB (%) | 565 (62.8) |
other anti-HT drugs (%) | 315 (35.0) |
Vitamin D (%) | 174 (19.3) |
Calcium agents (%) | 271 (30.1) |
Iron agents (%) | 85 (9.4) |
AST-120 (%) | 160 (17.8) |